Obesity affects approximately 100 million Indian adults and is linked to over 200 health complications, including heart ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

American pharmaceutical company Eli Lilly has launched its drug, Mounjaro, in India. Mounjaro is administered as a ...

Eli Lilly (LLY) launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk (NVO) for a much-awaited entry into the world’s most populous country ...

Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Mounjaro, an injectable medication designed to support weight loss, works by imitating the effects of two natural hormones, ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

The widely used anti-diabetes and weight loss drug Mounjaro, which contains the active ingredient tirzepatide, is now ...

Eli Lilly launches Mounjaro in India addressing diabetes-obesity crisis. Approved by CDSCO yet high costs limit accessibility ...